Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical experience with Mercilon and Marvelon with special reference to ovarian function].

M Mall-Haefeli1, I Werner-Zodrow, P R Huber

  • 1Universitäts-Frauenklinik Basel.

Geburtshilfe Und Frauenheilkunde
|January 1, 1991
PubMed
Summary

Comparing two oral contraceptives, Mercilon (0.020 mg ethinylestradiol) and Marvelon (0.030 mg ethinylestradiol), revealed distinct hormonal effects and cycle control differences. Mercilon showed less suppressed FSH and more breakthrough bleeding, while both were well-tolerated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical considerations in the certification of civil airmen.

The Journal of aviation medicine·2010
Same author

Value of gonadotropin-releasing hormone testing in the differential diagnosis of androgen deficiency in elderly men.

The Journal of clinical endocrinology and metabolism·2004
Same author

Disordered calcium homeostasis of sepsis: association with calcitonin precursors.

European journal of clinical investigation·2000
Same author

S100A1, a new marker for acute myocardial ischemia.

Biochemical and biophysical research communications·2000
Same author

Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit.

Critical care medicine·2000
Same author

General anaesthesia for surgery can influence circulating melatonin during daylight hours.

Acta anaesthesiologica Scandinavica·1998

Area of Science:

  • Endocrinology
  • Pharmacology
  • Reproductive Health

Background:

  • Oral contraceptives (OCs) are widely used for pregnancy prevention and managing gynecological conditions.
  • Ethinylestradiol (EE) and desogestrel are common components in combined OCs.
  • Different dosages of EE may influence hormonal profiles and cycle control.

Purpose of the Study:

  • To compare the effects of two oral contraceptive combinations: Mercilon (0.020 mg EE + 0.150 mg desogestrel) and Marvelon (0.030 mg EE + 0.150 mg desogestrel).
  • To assess hormonal profiles (LH, FSH, prolactin, progesterone, estradiol, SHBG) and clinical outcomes (efficacy, cycle control, tolerability).

Main Methods:

  • Two independent trials were conducted.
  • Trial 1: 71 women, serum hormone levels measured before, during (3rd and 6th cycle), and after treatment.

Related Experiment Videos

  • Trial 2: 781 women (5193 cycles), assessed efficacy, cycle control, and tolerability at 1st, 3rd, and 12th cycles.

    • Main Results:

    • Mercilon (lower EE dose) resulted in significantly less suppressed FSH compared to Marvelon.
    • Estradiol and progesterone levels were suppressed with Mercilon; some users showed extremely high levels.
    • Sex hormone-binding globulin (SHBG) increased significantly with both OCs; prolactin and testosterone levels were unaffected. Mercilon had more breakthrough bleedings (7.7%) and body weight changes than Marvelon (3.6%). Marvelon was associated with slightly more breast tenderness.

    Conclusions:

    • Both Mercilon and Marvelon demonstrate comparable efficacy and tolerability, with minor differences in hormonal suppression and cycle control.
    • The lower ethinylestradiol dose in Mercilon leads to less FSH suppression but a higher incidence of breakthrough bleeding and body weight changes.
    • Higher ethinylestradiol dose in Marvelon is associated with slightly more breast tenderness but fewer breakthrough bleedings.